Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc. is classed by the SEC under Measuring & Controlling Devices, NEC (industry code 3829), based in Waltham, MA. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $45 billion and a profit of $6.7 billion (its filed statements).
vs its business-model standard
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a product business: prior from its industry code (SEC 3829, Measuring & Controlling Devices, NEC); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 6.4 out of ten, 9 of 9 metrics filed: past 7.9 out of ten, present 6.9 out of ten, future 4.1 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
- Surviving crises (past): 8.2 out of ten. No warning events in its filings since 2017. 82nd percentile among 11 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Track record (past): 8.0 out of ten. +10.4% a year over 10 filed years; profitable in 3 of 3. 80th percentile among 11 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Shareholder treatment (past): 7.2 out of ten. Share count shrank 1.4% a year. 47% of cash flow returned. Insiders: 160 sales, 0 purchases. 72nd percentile among 6 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Financial health (present): 6.1 out of ten. ROE 13%: 13¢ of profit per shareholder dollar. Leverage 52%: owes 52¢ per asset dollar. 61st percentile among 11 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Industry position (present): 7.2 out of ten. top 28% of 11 in its family; net margin 15%. 72nd percentile among 11 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Leadership (present): 8.0 out of ten. top 20% of 9 in its family for leadership; chief executive since 2009. 80th percentile among 9 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
- Room to expand (future): 2.8 out of ten. bottom 28% of 10 in its family for room to expand. 28th percentile among 10 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Growth drivers (future): 4.3 out of ten. bottom 44% of 11 in its family for growth drivers. 44th percentile among 11 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Expectations vs reality (future): 6.4 out of ten. top 36% of 10 in its family for expectations against reality. 64th percentile among 10 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 10-K filed 2026-02-26 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-07-31 for the period ended 2026-06-27 (on EDGAR). Newest results release: Form 8-K filed 2026-07-23 (on EDGAR). Newest filing: Form 4, 2026-09-29. Filings on record since 1994. Read from EDGAR 2026-10-12.
Where the revenue comes from
Lines of business in fiscal 2025: Laboratory Products and Biopharma Services 54%, Life Sciences Solutions 20%, Analytical Instruments 17%, Specialty Diagnostics 10%. By geography: North America 52%, Europe 27%, Asia-Pacific 18%, Other regions 4%. As tagged in its annual report (Form 10-K, filed 2026-02-26).
Who runs it
Casper, Marc N (Chairman & CEO); Meyer, James (Sr. Vice President & CFO); Pettiti, Gianluca (President & COO); Shafer, Michael D (Executive Vice President); Lagarde, Michel (Executive Vice President); Lowery, Frederick M. (Executive Vice President); Williamson, Stephen (Retiring Sr. VP and CFO); Britt, Lisa P. (Sr. VP and Chief HR Officer); Holmes, Joseph R. (VP & Chief Accounting Officer); Shropshire, Thomas B Jr. (SVP and General Counsel); and 10 more. 20 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.
This file: Overview · Past · Present · Future · Filings · every company on file
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.